Ivonescimab

Small cell lung cancer (SCLC) often responds well initially but later relapses. New treatments like Imdelltra, Trilaciclib, Durvalumab, and Lurbinectedin have been FDA approved. Clinical trials are ongoing for treatments like Ivonescimab, PM8002, Adebelimab, IBI3009, YL201, ZG006, and Tarlatamb, focusing on extensive stage SCLC.

Akeso Biopharma announces first patient enrollment in Phase III AK112-309 trial for biliary tract tumor, comparing ivonescimab with durvalumab. The study aims to improve overall survival in advanced biliary tract cancers, following positive Phase II results showing significant antitumor activity and safety.

Akeso Biopharma announces first patient enrollment in Phase 3 trial of ivonescimab combination for biliary tract tumors, comparing it to durvalumab. The trial aims to establish ivonescimab as a first-line therapy, with overall survival as the primary endpoint.

Akeso Biopharma announces first patient enrollment in Phase 3 trial of ivonescimab combination for first-line therapy in biliary tract tumors, comparing it to durvalumab.

Akeso Biopharma enrolls first patient in Phase III trial (AK117-302) for head and neck squamous cell carcinoma, evaluating PD-1/VEGF bispecific antibody ivonescimab with CD47 monoclonal antibody ligufalimab against pembrolizumab. The trial marks a global first for CD47 monoclonal antibody therapy in solid tumors and highlights Akeso's commitment to advancing cancer immunotherapy.

Summit Therapeutics reports Q3 and 9-month 2024 progress, including ivonescimab's clinical success in NSCLC, raising $235M in private financing, and operational updates on Phase III trials.

EF Hutton analyst Jason Kolbert initiated coverage of ImmunityBio with a Buy rating and a $30 price target, implying a 767% upside. ImmunityBio's Anktiva, approved by the FDA for non-muscle invasive bladder cancer, activates the immune system to eliminate tumor cells and convert cold tumors into hot ones, potentially improving outcomes in various cancers.

Recent lung cancer meetings showcased ADCs compared to PD-1/PD-L1 inhibitors, with ivonescimab (AK112) showing improved PFS in PD-L1+ NSCLC. An ADC also demonstrated better PFS and response rates than pembrolizumab. In extensive-stage small cell lung cancer, ifinatamab deruxtecan showed dose-response benefits, suggesting potential for targeted therapies.

Q3 2024 saw approval of 5 novel antibody drugs, increased ADC research, and $3B in collaborations. Investment in antibodies continues, with startups raising up to $370M. Promising antibodies for Q4 include treatments for genetic disorders and cancers.